Somewhat Positive Media Coverage Likely to Affect ArQule (ARQL) Stock Price

News stories about ArQule (NASDAQ:ARQL) have been trending somewhat positive on Tuesday, according to Alpha One Sentiment Analysis. The research group, a unit of Accern, identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Alpha One ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. ArQule earned a daily sentiment score of 0.08 on Alpha One’s scale. Alpha One also gave news stories about the biotechnology company an impact score of 75 out of 100, meaning that recent media coverage is likely to have an effect on the stock’s share price in the immediate future.

Insider Buying and Selling by Quarter for ArQule (NASDAQ:ARQL)

Shares of ArQule (NASDAQ ARQL) opened at 1.13 on Tuesday. The firm’s market cap is $80.39 million. The stock has a 50 day moving average of $1.11 and a 200 day moving average of $1.23. ArQule has a 12 month low of $0.92 and a 12 month high of $2.17.

ArQule (NASDAQ:ARQL) last announced its quarterly earnings results on Wednesday, May 3rd. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.11). ArQule had a negative net margin of 482.44% and a negative return on equity of 95.33%. During the same period in the prior year, the firm posted ($0.08) earnings per share. On average, equities research analysts expect that ArQule will post ($0.44) EPS for the current fiscal year.

Separately, Zacks Investment Research upgraded shares of ArQule from a “sell” rating to a “hold” rating in a research report on Wednesday, March 8th.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://sportsperspectives.com/2017/06/20/arqule-arql-earning-somewhat-positive-press-coverage-report-finds-updated-updated-updated.html.

ArQule Company Profile

ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.

Receive News & Ratings for ArQule Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply